Aura Biosciences, Inc. Common Stock

AURANASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
6.12 USD
↘ 0.05 (0.78%)🟢PRE MARKET (AS OF 05:56 AM EDT)
🟢Market: OPEN

AURA is currently priced at $6.12. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation side, AURA appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Oct 6, 2026.

Open?$6.17
High?$6.17
Low?$6.12
Prev. Close?$6.17
Volume?17
Avg. Volume?863.0K
VWAP?$6.17
Rel. Volume?0.00x
Bid / Ask
Bid?$4.38 × 100
Ask?$6.99 × 100
Spread?$2.61
Midpoint?$5.69
Valuation & Ratios
Market Cap?639.9M
Shares Out?103.7M
Float?92.4M
Float %?89.1%
P/E Ratio?N/A
P/B Ratio?2.03
EPS?-$1.26
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Precision Medicine Platforms
Employees
113
Market Cap
645.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.aurabiosciences.com
Listed
2021-10-29
Address
80 GUEST STREET
BOSTON, MA 02135
Phone: (617)500-8864
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
65
Short Sent.?
23
Piotroski F-Score?0/9Weak
Altman Z-Score?9.19Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?7.63%Elevated
Short Interest?7.0M
Days to Cover?11.7
Free Float92.4M
Avg Daily Volume604.7K
Settlement Date2026-09-15
Financial Health
Current Ratio?16.82Strong
Quick Ratio?16.82Strong
Cash Ratio?3.47Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
73
2.03CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-4.2CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-41.6%WEAK▾
ROA?
S&P
3
-37.6%WEAK▾
Cash Flow & Enterprise
FCF?$-103351000
Enterprise Value?$572.0M
Fundamentals ratios updated end of day
MarketsMoversWatchlist